Composition and method of treatment for dry a.m.d. (age related macular degeneration)

A macular degeneration and composition technology, which is applied in the directions of drug combination, pharmaceutical formulation, drug delivery, etc.

Pending Publication Date: 2020-11-03
EYE CO PTY LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, Singh noted that AREDS failed to demonstrate that vita

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition and method of treatment for dry a.m.d. (age related macular degeneration)
  • Composition and method of treatment for dry a.m.d. (age related macular degeneration)
  • Composition and method of treatment for dry a.m.d. (age related macular degeneration)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0121] method

[0122] Animals and Exposure:

[0123] All experiments performed were in accordance with the ARVO Statement - Use of Animals in Ophthalmic and Vision Research. Sprague-Dawley (SD) rats at postnatal 130-160 days were exposed to 1000 lux of bright continuous light (BCL). The rats were born and raised under dim periodic light conditions (12 hours of light: 12 hours of darkness), and the ambient light level was about 5 lux. Animals between 90-150 days postpartum (P) were exposed to BCL. Rats were dark-adapted for at least 15 hours prior to BCL exposure and then transferred to individual cages designed to allow unobstructed light access. There were no shaded areas in the cage; pupil dilation was not performed. BCL exposures always started at 9:00 am and were achieved by using a cool white fluorescent light source (18W, cool white; TFC) positioned above the cage with an intensity of approximately 1000 lux at the bottom of the cage. BCL exposure was continued for ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Lengthaaaaaaaaaa
Login to view more

Abstract

A method of treating dry AMD in a subject comprising administering to the subject a therapeutically effective amount of an anti-inflammatory to thereby treat the dry AMD is disclosed. Also disclosed is a pharmaceutical composition comprising a therapeutically effective amount of one or more anti-inflammatory and a pharmaceutically acceptable carrier, diluent or excipient when used to treat dry AMDand use of the pharmaceutical composition for the manufacture of a medicament for the treatment of dry AMD. The one or more anti-inflammatory may comprise one or more of a COX inhibitor, one or moremineralocorticoid or a therapeutically active analogue, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof, one or more glucocorticoid or a therapeutically active analogue, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof, an antileukotrine and/or a leukotriene receptor antagonist. In one embodiment the anti-inflammatory comprises fludrocortisone.

Description

technical field [0001] The present invention relates to a composition and method for treating dry age-related macular degeneration (A.M.D or AMD). More specifically, the present invention relates to compositions and methods for treating dry AMD containing one or more anti-inflammatory drugs. Background technique [0002] It is generally accepted that there is no medical or surgical cure for dry AMD. [0003] Aruna Gorusupudi, Kelly Nelson, and Paul S Bernstein point out that multiple nutrients, such as minerals, vitamins, v-3 (n-3) fatty acids, and various carotenoids, have been consistently associated with a lower risk of AMD. These authors noted that results from the Age-Related Eye Disease Study (AREDS) showed that supplementation with antioxidants (b-carotene and vitamins C and E) and zinc was associated with a reduced risk of AMD progression, AREDS2 A follow-up study aimed to refine the earlier formula, testing the addition of lutein, zeaxanthin, and v-3 fatty acids. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/573A61P27/02A61K31/58A61K39/395
CPCA61P27/02A61K31/573A61K31/58A61K9/0019A61K9/0048A61K2300/00A61K38/1866A61K39/395A61K38/179A61K45/06A61K47/38A61K47/26A61K47/02
Inventor P·L·彭福尔德
Owner EYE CO PTY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap